

## Human CD137/4-1BB/TNFRSF9 (C-His-Avi)

<b>Catalog Number:</b>	808401, 808402
<b>Size:</b>	25 ug, 100 ug
<b>Target Name:</b>	TNFRSF9, 4-1BB, CD137
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---

<b>Application:</b>	ELISA, BLI
<b>Format:</b>	Liquid, Purified
<b>Expression Host:</b>	CHO
<b>Species:</b>	Human
<b>Sources:</b>	Recombinant Human CD137/4-1BB Protein (Leu24-Gln186) with C-terminus His-Avi-tag is expressed in CHO cell.
<b>Accession Number:</b>	Q07011
<b>Molecular Weight:</b>	The protein has a predicted molecular weight of 20.9 kDa. Under DTT-reducing conditions, it migrates at approximately 30 kDa on SDS-PAGE.
<b>Affinity Tag:</b>	C-His-Avi
<b>Purity:</b>	>95% based on SDS-PAGE under reducing condition
<b>Formulation:</b>	1xPBS buffer, pH7.4, 0.22 µm filtered
<b>Endotoxin level:</b>	Less than 0.1 EU/µg protein as determined by the LAL method
<b>Protein Concentration:</b>	25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
<b>Storage and Handling:</b>	Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

### BACKGROUND INFORMATION


---

CD137 (4-1BB) is a co-stimulatory glycoprotein from the tumor necrosis factor (TNF) receptor superfamily, expressed on activated CD4+ and CD8+ T cells. It binds to its ligand, 4-1BBL, found on antigen-presenting cells like macrophages and activated B cells. The interaction between CD137 and 4-1BBL triggers signaling through tumor necrosis factor receptor-associated factors (TRAFs), activating pathways like NF-kappaB and cytokine production. This process promotes T cell activation, proliferation, and immune responses, as well as monocyte and B-cell activation. CD137 and 4-1BBL are present in various human tumors, suggesting they may influence tumor progression. Crosslinking CD137 has shown promise in enhancing anti-tumor immunity in preclinical models,

and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Additionally, soluble CD137 (sCD137) can antagonize the membrane-bound form's function, reducing T cell proliferation and IL-2 secretion.

## PRODUCT DATA

---



Human 4-1BB Protein (C-His-Avi) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95%.

This product is supplied subject to the terms and conditions at [www.innocyto.com/web/terms.php](http://www.innocyto.com/web/terms.php) and may only be used as provided in the stated terms. Products are for Research Use Only.